PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5...

Por Mahalingam, D., Patel, M., Sachdev, J., Hart, L., Halama, N., Ramanathan, R., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Adib, D., Kerschbaumer, R., Yoon, M., Manzur, G., Starodub, A., Sivarajan, K., Wertheim, M., Thambi, P., Jones, M., Goel, S., Nemunaitis, J., Tsimberidou, A.
Publicado no Ann Oncol (2016)

Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Everolimus in Advanced Solid Tumors

Por Rangwala, F., Bendell, J., Kozloff, M., Arrowood, C., Dellinger, A., Meadows, J., Tourt-Uhlig, S., Murphy, J., Meadows, K.L., Starr, A., Broderick, S., Brady, J.C., Cushman, S. M., Morse, M., Uronis, H., Hsu, S.D., Zafar, S.Y., Wallace, J., Starodub, A., Strickler, J., Pang, H., Nixon, A.B., Hurwitz, H.
Publicado em 2014